Add to favourites

Programme introduction/Aims and objectives

Scotland has one of the highest incidence of adenocarcinoma in Europe.  Overall incidence of oesophageal adenocarcinoma is 6x higher that in the 1990s, with annual incidence now around 18/100,000 per population.  Approximately 900 cases per annum.

Impact of COVID-19 on Gastroenterology has meant endoscopy procedures being paused due to aerosol generating procedure (AGP) concerns.  Ongoing infection control requirements mean activity is significantly below pre-COVID levels.

Workstream aims and objectives:

  • To support the rollout and implementation of Cytosponge across NHS Scotland as a safe and effective alternative, non-AGP procedure to traditional upper endoscopy for the early detection of oesophageal adenocarcinoma
  • The Cytosponge pathway will be used for new reflux and Barrett’s Surveillance patient groups
  • To monitor the uptake and further expansion of service across NHS Boards through ‘Train the Trainer’
  • Development of a business case to undertake economic analysis of this intervention across NHS Scotland
  • Development of a Registry for prospective data collection of Cytosponge outcomes and onward pathways

For further information regarding this workstream please contact the MPPP/SAC team.

Current Progress and Expected Outcomes
  • Training staff in Health Boards to utilise the Cytosponge procedure ongoing
  • Improved access to Diagnostics and earlier diagnosis of pre or early cancer
  • Reduction in demand for Endoscopy
  • Improved patient experience
Contact Us

To contact the MPPP/SAC team, please email us at


Follow CfSD via Twitter @NHSScotCfSD